Evidence map›Paper›PMID 30049515›Full record

ArticleClinical lymphoma, myeloma & leukemia2018

Bone Health and Survival in Women With Multiple Myeloma.

Ashley E Rosko, Erinn M Hade, Wenjun Li, Steven Ing, Rebecca D Jackson, Electra D Paskett, Michelle J Naughton

Open access · greenAbstract read
In one paragraph

Article in Clinical lymphoma, myeloma & leukemia, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.5field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Ashley E RoskoDivision of Hematology, The Ohio State University, Columbus, OH. Electronic address: Ashley.Rosko@osumc.edu.
Erinn M HadeDepartment of Biomedical Informatics, The Ohio State University, Columbus, OH.
Wenjun LiDivision of Preventive and Behavioral Medicine, Department of Medicine, University of Massachusetts Medical School, Worcester, MA.
Steven IngDivision of Endocrinology, Diabetes, and Metabolism, The Ohio State University, Columbus, OH.
Rebecca D JacksonDivision of Endocrinology, Diabetes, and Metabolism, The Ohio State University, Columbus, OH.
Electra D PaskettCancer Prevention and Control, The Ohio State University, Columbus, OH.
Michelle J NaughtonCancer Prevention and Control, The Ohio State University, Columbus, OH.
The Ohio State University · USUniversity of Massachusetts Chan Medical School · US

Funding

Exercise and Biologic Fitness in Patients with Hematologic MalignancyK23CA208010 · NCI · OHIO STATE UNIVERSITY · PI ROSKO, ASHLEY E. · 2016 to 2020
$859k
NCI NIH HHS K23 CA208010NHLBI NIH HHS HHSN268201600001CNHLBI NIH HHS HHSN268201600002CNHLBI NIH HHS HHSN268201600003CNHLBI NIH HHS HHSN268201600004CNHLBI NIH HHS HHSN268201600018C
6 · The paper itself

Abstract

backgroundMultiple myeloma (MM) is a disease of aging adults resulting in osteolytic and/or osteoporotic bone disease. Primary osteoporosis is also highly prevalent in aging adults and is associated with increased mortality. It is unknown how concurrent osteoporosis is associated with outcomes in patients who develop MM. PATIENTS AND

methodsWe identified 362 women with MM of the 161,808 enrolled in the Women's Health Initiative (WHI) dataset and evaluated bone health using the Fracture Risk Assessment Tool (FRAX) to identify clinical factors that affect overall MM survival in post-menopausal women, as measured from the time of diagnosis.

resultsOf the 362 participants who developed incident MM, with an average 10.5 years of follow-up, 226 died, including 71 with high FRAX scores and 155 with low FRAX scores. On average, women with high FRAX scores were 8.3 years older at enrollment (95% confidence interval [CI], 7.2-9.3 years) and 8.0 years older at time of MM diagnosis (95% CI, 7.0-9.2 years) compared with those with low FRAX scores. MM mortality for women with high FRAX scores was greater (covariate-adjusted hazard ratio scores [aHR] 1.51; 95% CI, 1.01-2.25; P = .044) compared with those with low FRAX scores.

conclusionHigher fracture risk, measured by FRAX, was associated with higher MM mortality in post-menopausal women, independent of many other clinical factors.

Indexed as

Bone DensityAgedAged, 80 and overFemaleFollow-Up StudiesHumansLongitudinal StudiesMiddle AgedMultiple MyelomaOsteoporosis, PostmenopausalPrognosisSurvival RateFRAXGeriatricMGUSMultiple myelomaOsteoporosis

Identifiers

PMID30049515
PMCPMC6559348
OpenAlexW2806085006

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.